Chapter/Section Purchase

1 Proto-Oncogene Drgu Market Overview
1.1 Product Overview and Scope of Proto-Oncogene Drgu
1.2 Proto-Oncogene Drgu Segment by Type
1.2.1 Global Proto-Oncogene Drgu Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Axitinib (Inlyta)
1.2.3 Ponatinib (Iclusig)
1.2.4 Imatinib (Gleevec)
1.2.5 Sunitinib (Sutent)
1.2.6 Pazopanib (Votrient)
1.2.7 Dabrafenib (Tafinlar)
1.2.8 Vandetanib (Caprelsa)
1.2.9 Vemurafenib (Zelboraf)
1.2.10 Cabozantinib (Cabometyx and Cometriq)
1.2.11 Sorafenib (Nexavar)
1.3 Proto-Oncogene Drgu Segment by Application
1.3.1 Global Proto-Oncogene Drgu Sales Comparison by Application: (2022-2028)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Proto-Oncogene Drgu Market Size Estimates and Forecasts
1.4.1 Global Proto-Oncogene Drgu Revenue 2017-2028
1.4.2 Global Proto-Oncogene Drgu Sales 2017-2028
1.4.3 Proto-Oncogene Drgu Market Size by Region: 2017 Versus 2021 Versus 2028
2 Proto-Oncogene Drgu Market Competition by Manufacturers
2.1 Global Proto-Oncogene Drgu Sales Market Share by Manufacturers (2017-2022)
2.2 Global Proto-Oncogene Drgu Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Proto-Oncogene Drgu Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Proto-Oncogene Drgu Manufacturing Sites, Area Served, Product Type
2.5 Proto-Oncogene Drgu Market Competitive Situation and Trends
2.5.1 Proto-Oncogene Drgu Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Proto-Oncogene Drgu Players Market Share by Revenue
2.5.3 Global Proto-Oncogene Drgu Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Proto-Oncogene Drgu Retrospective Market Scenario by Region
3.1 Global Proto-Oncogene Drgu Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Proto-Oncogene Drgu Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Proto-Oncogene Drgu Market Facts & Figures by Country
3.3.1 North America Proto-Oncogene Drgu Sales by Country
3.3.2 North America Proto-Oncogene Drgu Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Proto-Oncogene Drgu Market Facts & Figures by Country
3.4.1 Europe Proto-Oncogene Drgu Sales by Country
3.4.2 Europe Proto-Oncogene Drgu Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Proto-Oncogene Drgu Market Facts & Figures by Region
3.5.1 Asia Pacific Proto-Oncogene Drgu Sales by Region
3.5.2 Asia Pacific Proto-Oncogene Drgu Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Proto-Oncogene Drgu Market Facts & Figures by Country
3.6.1 Latin America Proto-Oncogene Drgu Sales by Country
3.6.2 Latin America Proto-Oncogene Drgu Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Proto-Oncogene Drgu Market Facts & Figures by Country
3.7.1 Middle East and Africa Proto-Oncogene Drgu Sales by Country
3.7.2 Middle East and Africa Proto-Oncogene Drgu Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Proto-Oncogene Drgu Historic Market Analysis by Type
4.1 Global Proto-Oncogene Drgu Sales Market Share by Type (2017-2022)
4.2 Global Proto-Oncogene Drgu Revenue Market Share by Type (2017-2022)
4.3 Global Proto-Oncogene Drgu Price by Type (2017-2022)
5 Global Proto-Oncogene Drgu Historic Market Analysis by Application
5.1 Global Proto-Oncogene Drgu Sales Market Share by Application (2017-2022)
5.2 Global Proto-Oncogene Drgu Revenue Market Share by Application (2017-2022)
5.3 Global Proto-Oncogene Drgu Price by Application (2017-2022)
6 Key Companies Profiled
6.1 ARIAD Pharmaceuticals
6.1.1 ARIAD Pharmaceuticals Corporation Information
6.1.2 ARIAD Pharmaceuticals Description and Business Overview
6.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.1.4 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
6.1.5 ARIAD Pharmaceuticals Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AstraZeneca Proto-Oncogene Drgu Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Bayer Healthcare
6.3.1 Bayer Healthcare Corporation Information
6.3.2 Bayer Healthcare Description and Business Overview
6.3.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Bayer Healthcare Proto-Oncogene Drgu Product Portfolio
6.3.5 Bayer Healthcare Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 ChemGenex Pharmaceuticals
6.5.1 ChemGenex Pharmaceuticals Corporation Information
6.5.2 ChemGenex Pharmaceuticals Description and Business Overview
6.5.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.5.4 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
6.5.5 ChemGenex Pharmaceuticals Recent Developments/Updates
6.6 Dexa Medica
6.6.1 Dexa Medica Corporation Information
6.6.2 Dexa Medica Description and Business Overview
6.6.3 Dexa Medica Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Dexa Medica Proto-Oncogene Drgu Product Portfolio
6.6.5 Dexa Medica Recent Developments/Updates
6.7 Eisai Pharmaceuticals
6.6.1 Eisai Pharmaceuticals Corporation Information
6.6.2 Eisai Pharmaceuticals Description and Business Overview
6.6.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
6.7.5 Eisai Pharmaceuticals Recent Developments/Updates
6.8 Exelixis
6.8.1 Exelixis Corporation Information
6.8.2 Exelixis Description and Business Overview
6.8.3 Exelixis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Exelixis Proto-Oncogene Drgu Product Portfolio
6.8.5 Exelixis Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.9.4 GlaxoSmithKline Proto-Oncogene Drgu Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Novartis Proto-Oncogene Drgu Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Onyx Pharmaceuticals
6.11.1 Onyx Pharmaceuticals Corporation Information
6.11.2 Onyx Pharmaceuticals Proto-Oncogene Drgu Description and Business Overview
6.11.3 Onyx Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
6.11.5 Onyx Pharmaceuticals Recent Developments/Updates
6.12 Plexxikon
6.12.1 Plexxikon Corporation Information
6.12.2 Plexxikon Proto-Oncogene Drgu Description and Business Overview
6.12.3 Plexxikon Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Plexxikon Proto-Oncogene Drgu Product Portfolio
6.12.5 Plexxikon Recent Developments/Updates
6.13 Pfizer
6.13.1 Pfizer Corporation Information
6.13.2 Pfizer Proto-Oncogene Drgu Description and Business Overview
6.13.3 Pfizer Proto-Oncogene Drgu Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Pfizer Proto-Oncogene Drgu Product Portfolio
6.13.5 Pfizer Recent Developments/Updates
7 Proto-Oncogene Drgu Manufacturing Cost Analysis
7.1 Proto-Oncogene Drgu Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Proto-Oncogene Drgu
7.4 Proto-Oncogene Drgu Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Proto-Oncogene Drgu Distributors List
8.3 Proto-Oncogene Drgu Customers
9 Proto-Oncogene Drgu Market Dynamics
9.1 Proto-Oncogene Drgu Industry Trends
9.2 Proto-Oncogene Drgu Market Drivers
9.3 Proto-Oncogene Drgu Market Challenges
9.4 Proto-Oncogene Drgu Market Restraints
10 Global Market Forecast
10.1 Proto-Oncogene Drgu Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Proto-Oncogene Drgu by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Proto-Oncogene Drgu by Type (2023-2028)
10.2 Proto-Oncogene Drgu Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Proto-Oncogene Drgu by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Proto-Oncogene Drgu by Application (2023-2028)
10.3 Proto-Oncogene Drgu Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Proto-Oncogene Drgu by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Proto-Oncogene Drgu by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer